Log in

NASDAQ:CBLICleveland BioLabs Insider Trades

$2.24
0.00 (0.00 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.21
Now: $2.24
$2.42
50-Day Range
$1.52
MA: $2.02
$4.26
52-Week Range
$0.50
Now: $2.24
$5.00
Volume525,800 shs
Average Volume3.52 million shs
Market Capitalization$25.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Insider Trades

Cleveland BioLabs (NASDAQ:CBLI) Insider Buying and Selling Activity

Insider Ownership Percentage: 1.88%

Insider Buying and Selling by Quarter


Cleveland BioLabs (NASDAQ CBLI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/25/2015Randy S SaluckDirectorBuy1,891$3.42$6,467.22  
5/21/2013Paul E DicorletoDirectorBuy6,210$1.61$9,998.10  
5/17/2013Randy S SaluckDirectorBuy3,500$1.60$5,600.00  
3/15/2013James AntalDirectorBuy3,700$1.56$5,772.00  
9/21/2012James AntalDirectorBuy2,316$2.60$6,021.60  
(Data available from 1/1/2013 forward)
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.